• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

嵌合抗原受体T细胞疗法治疗肺移植后难治性移植后淋巴细胞增殖性疾病

Chimeric antigen receptor T-cell therapy for refractory post-transplant lymphoproliferative disorder after lung transplantation.

作者信息

Veit Kaleb, Peña Tahuanty, Klesney-Tait Julia, Mou Eric, Farooq Umar

机构信息

University of Nebraska Medical Center, Omaha, Nebraska.

University of Iowa Hospitals and Clinics, Iowa City, Iowa.

出版信息

JHLT Open. 2024 Apr 25;5:100101. doi: 10.1016/j.jhlto.2024.100101. eCollection 2024 Aug.

DOI:10.1016/j.jhlto.2024.100101
PMID:40143897
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11935479/
Abstract

Chimeric antigen receptor T-cell therapy (CAR-T) has been used to treat refractory post-transplant lymphoproliferative disorder (PTLD) in solid organ transplant patients, including heart, kidney, liver, intestine, and pancreas. We report the use of CAR-T for treating refractory PTLD in a 73-year-old female who was 7 years post bilateral lung transplantation for idiopathic pulmonary fibrosis. We discuss the immunosuppression management in this patient, as well as her clinical course and outcome.

摘要

嵌合抗原受体T细胞疗法（CAR-T）已被用于治疗实体器官移植患者的难治性移植后淋巴细胞增生性疾病（PTLD），这些患者包括心脏、肾脏、肝脏、肠道和胰腺移植患者。我们报告了一名73岁女性患者，她因特发性肺纤维化接受双侧肺移植7年后，使用CAR-T治疗难治性PTLD的情况。我们讨论了该患者的免疫抑制管理，以及她的临床病程和结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1952/11935479/0ec85d8624c4/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1952/11935479/c8ef183c5605/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1952/11935479/a32218fcd79f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1952/11935479/8a38e83ce741/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1952/11935479/0ec85d8624c4/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1952/11935479/c8ef183c5605/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1952/11935479/a32218fcd79f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1952/11935479/8a38e83ce741/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1952/11935479/0ec85d8624c4/gr4.jpg

相似文献

1
Chimeric antigen receptor T-cell therapy for refractory post-transplant lymphoproliferative disorder after lung transplantation.嵌合抗原受体T细胞疗法治疗肺移植后难治性移植后淋巴细胞增殖性疾病
JHLT Open. 2024 Apr 25;5:100101. doi: 10.1016/j.jhlto.2024.100101. eCollection 2024 Aug.
2
Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD).嵌合抗原受体 (CAR) T 细胞治疗移植后淋巴组织增生性疾病 (PTLD) 的肾移植患者。
Hum Vaccin Immunother. 2023 Aug 1;19(2):2216116. doi: 10.1080/21645515.2023.2216116. Epub 2023 Jun 6.
3
Treatment of post-transplant lymphoproliferative disorder (PTLD) in a heart transplant recipient with chimeric antigen receptor T-cell therapy.嵌合抗原受体T细胞疗法治疗心脏移植受者的移植后淋巴细胞增生性疾病（PTLD）
Pediatr Transplant. 2021 Aug;25(5):e13861. doi: 10.1111/petr.13861. Epub 2020 Oct 1.
4
CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder.嵌合抗原受体 T 细胞疗法治疗移植后难治性淋巴增殖性疾病的实体器官移植受者。
Am J Transplant. 2021 Feb;21(2):809-814. doi: 10.1111/ajt.16367. Epub 2020 Dec 5.
5
Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD.CD19 CAR-T 细胞治疗复发/难治性实体器官移植相关 PTLD 的安全性和生存的真实世界证据。
Br J Haematol. 2023 Jul;202(2):248-255. doi: 10.1111/bjh.18828. Epub 2023 May 2.
6
Successful Treatment of Refractory Post-Transplant Lymphoproliferative Disorder With Chimeric Antigen Receptor T-Cell Therapy in a Heart Transplant Recipient.心脏移植受者中嵌合抗原受体T细胞疗法成功治疗难治性移植后淋巴细胞增生性疾病
J Hematol. 2024 Apr;13(1-2):34-38. doi: 10.14740/jh1211. Epub 2024 Apr 9.
7
CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review.实体器官移植受者发生移植后淋巴细胞增生性疾病的CAR-T治疗：病例报告及文献综述
Curr Res Transl Med. 2021 Oct;69(4):103304. doi: 10.1016/j.retram.2021.103304. Epub 2021 Jul 22.
8
Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.抗 CD19 嵌合抗原受体 T 细胞疗法成功治疗肝移植后小儿难治性 Burkitt 淋巴瘤 PTLD。
Cell Transplant. 2021 Jan-Dec;30:963689721996649. doi: 10.1177/0963689721996649.
9
Kidney Transplant T Cell-Mediated Rejection Occurring After Anti-CD19 CAR T-Cell Therapy for Refractory Aggressive Burkitt-like Lymphoma With 11q Aberration: A Case Report.抗CD19嵌合抗原受体T细胞疗法治疗伴有11q畸变的难治性侵袭性伯基特样淋巴瘤后发生的肾移植T细胞介导的排斥反应：一例报告
Am J Kidney Dis. 2022 May;79(5):760-764. doi: 10.1053/j.ajkd.2021.07.012. Epub 2021 Aug 27.
10
Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder.病例报告：单倍体异基因干细胞移植后淋巴增殖性疾病患者接受嵌合抗原受体T细胞疗法取得成功
Front Oncol. 2021 Jul 22;11:709370. doi: 10.3389/fonc.2021.709370. eCollection 2021.

本文引用的文献

1
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.阿基仑赛治疗大 B 细胞淋巴瘤的总生存。
N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5.
2
Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD.CD19 CAR-T 细胞治疗复发/难治性实体器官移植相关 PTLD 的安全性和生存的真实世界证据。
Br J Haematol. 2023 Jul;202(2):248-255. doi: 10.1111/bjh.18828. Epub 2023 May 2.
3
Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT.
自体干细胞移植治疗实体器官移植后移植后淋巴组织增生性疾病：来自 EBMT 淋巴瘤工作组的回顾性分析。
Bone Marrow Transplant. 2021 Sep;56(9):2118-2124. doi: 10.1038/s41409-021-01270-5. Epub 2021 Apr 16.
4
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma.皮质类固醇对嵌合抗原受体 T 细胞疗法治疗大 B 细胞淋巴瘤疗效的预后影响。
Blood. 2021 Jun 10;137(23):3272-3276. doi: 10.1182/blood.2020008865.
5
CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder.嵌合抗原受体 T 细胞疗法治疗移植后难治性淋巴增殖性疾病的实体器官移植受者。
Am J Transplant. 2021 Feb;21(2):809-814. doi: 10.1111/ajt.16367. Epub 2020 Dec 5.
6
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.ASTCT 细胞因子释放综合征和免疫效应细胞相关神经系统毒性的共识分级标准。
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
7
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.19-28z嵌合抗原受体T细胞疗法治疗B细胞急性淋巴细胞白血病的疗效及毒性管理
Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.